Back

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: cardiometabolic medicine Obesity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Mamas Mamas

Keele University, Keele (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
CONFIDENCE: Results by KDIGO risk category
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
SGLT2i and AF
Doctor J. Sedighi (Giessen, DE)
Slides Video
Presentation thumbnail
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Ms L. Wilson (US)
Slides Video
Presentation thumbnail
STRIDE Outcomes by Sexl
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction
Doctor N. Kruger (Boston, US)

Access the full session

Session thumbnail
Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
How has the concept of incretin mimetics evolved since SELECT?
thumbnail
Congress Presentation
What's the next step in HFpEF?
thumbnail
Congress Presentation
Tackling the obesity tsunami: pharmacotherapy is the solution - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources